Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
A Partnership Focused on Improving Printing Processes with Biomaterials
Press Release June 15th, 2022
PHOENIX, Arizona - Puredyne has formed a strategic partnership with Humabiologics that is set to benefit researchers when it comes to printing collagen and gelatin. The collaboration between the two companies provides scientists with an integrated solution of printing precision through Puredyne kit b and the clinical relevance of Humabiologics human bioinks.
Humabiologics is a rapidly growing US regenerative medicine company based in Phoenix, Arizona focused on providing native human-derived collagen, gelatin, and extracellular matrices from donated human tissue. Humabiologics offers a number of products including HumaDerm, the most affordable native human skin collagen type I, and Huma OsteoGelMA, the market’s first native human gelatin methacrylate (GelMA). Their products are manufactured under an ISO 13845 quality system and comply with GMP standards, to provide researchers with the highest quality and clinically relevant solutions to support the development of translational regenerative therapies and drug discovery.
With a core mission to honor the gift of donated human tissue, Humabiologics promotes translational scientific advancements in biomaterials and 3D printing to develop lifesaving therapies and enhancing treatments. By offering human biomaterials that are high quality, affordable, and at a stable supply, it is their hope to accelerate translational medicine and empower tomorrow’s innovations.
The benefits of the collaboration between the two companies and the use of the Puredyne kit b are clear, as Humabiologics is now able to print human collagen and gelatin even more precisely – and thus also more cost-effectively.
“Puredyne’s printing platform has precise and impressive printing capabilities accommodating various bioink formulas with high fidelity. The plug-and-play print head addresses a number of common issues related to the bioink of choice with other printing platforms such as clogging, viscosity and concentration limitations, low cell viability, and other issues. We are excited to see the impact of such technologies for researchers around the globe.” says Madeline Damasco, Scientific Liaison at Humabiologics.
Printing biomaterials with high resolution to develop complex tissue models remains a challenge and a labor intense process. In addition, the volume of the bioink that is used in the printing process is often more than the volume needed to print the structure. This is mainly due to volume lost in channels of the dispensing platform including the bioink cartridge. Puredyne’s platform addresses these challenges through the progressive cavity technology used in the cartridge, which not only overcomes the different viscosity challenges, but also reduces the volume of bioink needed and reduces the cost.
“Our partnership with Humabiologics will advance the bioprinting sector as a whole. With the combined advantages of the Puredyne portfolio, and Humabiologics superior biomaterials, companies and universities will achieve reproducible research results and higher cell viability." said Annaliese Vojnich, Business Development Manager at ViscoTec America.
For users, a key highlight is the fact that the Puredyne kit b is very easy to use. When comparable technologies need complex process control systems, the Puredyne kit b sets itself apart by intuitively linking the screw’s rotating speed to the material flow rate in a linear relationship.
About Humabiologics
Humabiologics is a regenerative medicine company founded by scientists and tissue industry experts to address the gap between the gift of donated human tissues and researchers. Learn more at https://humabiologics.com
About Puredyne
Simply progressive. Simply usable. Simply pure.
Puredyne is a brand of ViscoTec Pumpen- u. Dosiertechnik GmbH. ViscoTec primarily deals in systems required for feeding, dosing, applying, filling, and extracting medium to high-viscosity media. The technological market leader has its headquarters in Töging in the Altötting district of Upper Bavaria, Germany. With subsidiaries in the USA, China, Singapore, India, France, and Hong Kong, ViscoTec employs around 300 people worldwide.
Contact:
Humabiologics, Inc
Madeline Damasco, Scientific Liaison
Telephone +01 (602) 786 - 6289
ViscoTec Pumpen- u. Dosiertechnik GmbH
Felix Gruber, Business Development Single Use
Amperstraße 13, D-84513 Töging a. Inn
Telephone +49 8631 9274-235
felix.gruber@viscotec.de · www.puredyne.com
ViscoTec Pumpen- u. Dosiertechnik GmbH
Lisa Kiesenbauer, Marketing
Amperstraße 13, D-84513 Töging a. Inn
Telephone +49 8631 9274-0
lisa.kiesenbauer@viscotec.de · www.viscotec.de
Press Release February 28th, 2022
PHOENIX, Arizona - Humabiologics, an industry leader in providing human-derived biomaterials for regenerative medicine, and Shanghai Besto Biotechnology Co., Ltd, a leader in distributing life science research supplies in China, has entered into a non-exclusive agreement to respond to the growing demand and serve a broader life sciences customer base of industry partners and academic institutions in the Chinese market.
Humabiologics develops and commercializes high quality and affordable human-derived biomaterials for translational regenerative medicine applications such as cell therapy, bioprinting, tissue & disease modeling, or drug screening.
“We are excited to add Shanghai Besto Biotechnology Co., Ltd to our growing list of distributors to make our human products more accessible to researchers in China. Our products are now accessible to researchers in US, Japan, China, and Europe”, said Dr. Mohammad Albanna, CEO & Founder of Humabiologics.
Shanghai Besto Biotechnology has been serving Chinese customers with products for cell culture, transfection, cryopreservation, and many other life science research lab products.
About Humabiologics
Humabiologics is a regenerative medicine company founded by scientists and tissue industry experts to address the gap between the gift of donated human tissues and researchers. Learn more at https://humabiologics.com
Contact:
Humabiologics, Inc
Dr. Mohammad Albanna, Founder & CEO
Press Release November 1, 2021
PHOENIX, Arizona - Humabiologics, an industry leader in providing human-derived biomaterials for regenerative medicine, and Funakoshi Co., Ltd, a leader in manufacturing and distributing life sciences research supplies for 50 years in Japan, has entered into a non-exclusive agreement to respond to the growing demand and serve a broader life sciences customer base of industry partners and academic institutions in the Japanese market.
Humabiologics develops and commercializes high quality and affordable human-derived biomaterials for translational regenerative medicine applications such as cell therapy, bioprinting, tissue & disease modeling, or drug screening.
“We are delighted to partner with Funakoshi to make our human products more accessible to researchers in Japan. Funakoshi is a strategic partner with long history and reputation of manufacturing and distributing of life sciences reagents and equipment for life sciences research”, said Dr. Mohammad Albanna, CEO & Founder of Humabiologics. “We look forward to a long-lasting relationship with Funakoshi and to serve their customers with our products to accelerate the development of life saving human therapies”.
Funakoshi has been offering several useful tools with leading edge technologies for Japanese researchers from all over the world to support and develop their research.
About Humabiologics
Humabiologics is a regenerative medicine company founded by scientists and tissue industry experts to address the gap between the gift of donated human tissues and researchers. Learn more at https://humabiologics.com
Contact:
Humabiologics, Inc
Dr. Mohammad Albanna, Founder & CEO
Press Release September 25, 2021
PHOENIX, Arizona - Humabiologics, an industry leader in providing human-derived biomaterials for regenerative medicine, is pleased to announce it is now ISO 13485:2016 certified and GMP compliant for the manufacturing of human-derived biomaterials. The scope of the certificate covers the design, manufacture, and distribution of human biomaterials, components, and sub-assemblies for use in research and development, medical devices, pharmaceuticals, and biologic products.
Humabiologics develops and commercializes high quality, affordable human-derived biomaterials for translational regenerative medicine applications such as cell therapy, bioprinting, tissue & disease modeling, and drug screening. Humabiologics recently introduced the world’s first native human collagen and gelatin-based bioinks. By becoming ISO 13485:2016 registered, Humabiologics has proven its ability to manufacture these biomaterials under strict regulatory conditions including those required under the FDA’s Good Manufacturing Practices (GMP).
“We are excited to continue our mission of providing clinically-relevant human-derived biomaterials under our GMP compliant ISO 13485 registered quality system to support our customers and partners for the development of regenerative human therapies and drug discovery”, said Dr. Mohammad Albanna, CEO & Founder of Humabiologics. “As the field is accelerating towards creating human organs and tissues and paving the way to eliminate the use of unreliable animal models for drug discovery, we remain focused on consistently providing high quality products to standardize these research endeavors around the world and reduce the time and cost that is needed to develop innovative personalized human therapies.
About Humabiologics
Humabiologics is a regenerative medicine company founded by scientists and tissue industry experts focused on narrowing the gap between the gift of donated human tissues and researchers by providing human-derived biomaterials. Learn more at https://humabiologics.com
Contact:
Humabiologics, Inc
Dr. Mohammad Albanna, Founder & CEO
Press Release August 2, 2021
PHOENIX, Arizona & SAN DIEGO, California - Humabiologics, an industry leader in providing human-derived biomaterials for regenerative medicine, and Allegro 3D, an emerging 3D bioprinting company, are partnering to accelerate the development of tissue models for drug screening and regenerative medicine therapies.
Humabiologics develops and commercializes high quality and affordable human-derived biomaterials for translational regenerative medicine applications such as cell therapy, bioprinting, tissue & disease modeling, or drug screening. Allegro 3D offers STEMAKER the world first digital light processing (DLP)-based bioprinter, capable of printing functional tissue models in mere seconds directly in multiwell plates.
“We are excited to partner with Allegro 3D to provide clinically-relevant human-derived biomaterials that allow for fabricating human tissue models for rapid drug screening”, said Dr. Mohammad Albanna, CEO & Founder of Humabiologics. “Our off-the-shelf human bioinks complementing Allegro 3D’s transformative bioprinting technology and we look forward to develop other bioink formulas through our partnership to support researchers who are looking for reliable alternatives to animal testing for drug discovery”.
Allegro 3D’s STEMAKERTM bioprinter creates a new paradigm for drug discovery, assay development, disease modeling, and regenerative medicine. It is one of the fastest and high resolution bioprinters, capable of producing live tissue constructs with intricate microscopic features, such as vascularized human liver tissues. Physiologically relevant tissue samples can be printed in seconds using the STEMAKER compared to hours by other traditional bioprinting platforms. When applied to high throughput combinatorial-screening platforms, Allegro 3D’s STEMAKER has great potential to increase the efficiency of the drug discovery process and reduce the use of the unreliable animal models.
“Allegro 3D aspires to accelerate precision medicine with our rapid high-throughput bioprinters and a wide selection of bioinks”, said Dr. Wei Zhu, CEO and Co-founder of Allegro 3D. “By partnering with Humabiologics, we are proud to be the first bioprinting company to provide total solutions for manufacturing clinically-relevant human tissues with human-derived biomaterials”.
Collaborations between the two companies have demonstrated the excellent biocompatibility and printability of the human-derived bioinks on the STEMAKER bioprinting platform. The human-derived bioinks are available for ordering on Allegro 3D’s website.
Humabiologics and Allegro 3D share the same mission to advance human healthcare with innovative bioprinting technologies and biomaterials. The joint force of the two companies will strive to provide transformative solutions to improve the efficiency and accuracy of drug discovery, provide predictive disease models, and develop patient-specific therapies.
About Humabiologics
Humabiologics is a regenerative medicine company founded by scientists and tissue industry experts to address the gap between the gift of donated human tissues and researchers. Learn more at https://humabiologics.com
About Allegro 3D
Allegro 3D offers the world’s first digital light processing (DLP)-based bioprinter for direct printing in multiwell plates. With its rapid printing speed, the STEMAKER bioprinter enables direct in-well printing of tissue constructs for high-throughput assays and screening. Learn more at https://allegro3d.com
Contact:
Humabiologics, Inc
Dr. Mohammad Albanna, Founder & CEO
(312) 479 5199
Allegro 3D, Inc
Dr. Wei Zhu, Co-founder & CEO
(858) 997-7741
Humabiologics introduced the world’s first native human collagen bioinks and gelatin bioinks. These bioinks are affordable and more clinically relevant, enabling researchers to advance the translational research of bioprinted human organs and tissues.
Humabiologics, a Phoenix-based startup that extends the gift of donation to provide human-derived biomaterials and stem cells to empower tomorrow’s innovations.
· Humabiologics products are used for translational regenerative medicine applications such as cell therapy, bioprinting, tissue & disease modeling, or drug screening.
· Humabiologics, Inc. human biomaterial products are available through global life science distributor VWR, part of Avantor, for use in regenerative medicine research applications.
Press Release May 24, 2021
PHOENIX, Ariz - Humabiologics, a regenerative medicine company founded by scientists and tissue industry experts to address the gap between the gift of donated human tissues and researchers, is pleased to announce its non-exclusive US partnering agreement with VWR, part of Avantor, Inc.
Humabiologics develops and commercializes high quality and affordable human-derived biomaterials for translational regenerative medicine applications such as cell therapy, bioprinting, tissue & disease modeling, or drug screening. VWR, part of Avantor, has thousands of quality products used daily in research laboratories around the world.
“Humabiologics provides affordable and more clinically-relevant human-derived biomaterials that allow researchers to advance the translational research of regenerative medicine therapies”, said Dr. Mohammad Albanna, CEO & Founder of Humabiologics. “Our partnership with VWR allows us to serve a broader life sciences customer base of industry partners and academic institutions.”
Humabiologics products are used by life science companies and academic researchers to develop innovative therapies that address debilitating diseases and improve the quality of life for patients.
The use of animal products in research can lead to poor translation aspects, irrelevant outcomes, and FDA regulatory hurdles that can slow the development of life science innovations. Humabiologics human-derived products are designed to address these challenges. Humabiologics developed proprietary processes to manufacture its products and only partners with FDA registered and accredited tissue banks around the US to utilize thoroughly screened donated human tissue that will not be used for transplant. Humabiologics product offering includes native human collagen, bone gelatin, and extracellular matrix.
Published* and ongoing collaborative data, utilizing these products by researchers around the world for different applications, highlighted the quality and relevance of the products for developing translational therapies.
“New and emerging heath solutions based on regenerative medical technologies have the potential to greatly improve the human condition,” said Joan Koerber-Walker, president & CEO of the Arizona Bioindustry Association. “Humabiologics offers a solution to a challenge that researchers face by providing access to high quality, stable supply of human biomaterials at an affordable price. By partnering with Avantor to deliver these products through VWR, Humabiologics is making it easier for researchers around the world to get the biomaterials they need to move this important science forward.”
About Humabiologics
Humabiologics is a regenerative medicine company founded by scientists and tissue industry experts to address the gap between the gift of donated human tissues and researchers. Learn more at https://humabiologics.com/.
Contact:
Humabiologics, Inc
Dr. Mohammad Albanna, Founder & CEO
(312) 479 5199
*Published Paper: https://pubmed.ncbi.nlm.nih.gov/32957839/
Ourobionics entered into a non-exclusive agreement with Humabiologics, a US biotech company specializing in the development and commercialization of human biomaterials for regenerative medicine research applications. The partnership agreement allows Humabiologics to respond to the growing demand and serve a broader life sciences customer base of industry partners and academic institutions in the European market. Under this agreement, European customers will have quick and convenient access to Humabiologics products through Ourobionics.
This grant is designed to catalyze growth and opportunities for Arizona's most promising startups and Humabiologics clearly demonstrated how these funds will drive our business forward.
Humabiologics is dedicated to providing human-derived biomaterials for tissue engineering and regenerative medicine. The company’s products are designed to be used alone or alongside other biomaterials in various fields like bio-printing, diagnostics and screening, pharmacology, and cell culture. Humabiologics’ mission is to provide biomaterials at an affordable price in order to help researchers innovate regenerative medicine therapies.
Humabiologics, Inc. is announcing its first HumaScholar Grant. Each HumaScholar will receive a $3,000 research grant in the form of credit to utilize human-derived biomaterials from Humabiologics. All proposed work must be completed between March 8th and May 28, 2021. Humabiologics will not own any rights for intellectual property, publications, or any other rights generated from the use of the grant money. The application deadline is 11:59pm EST on Friday, February 19, 2021. A total of 20 grants will be awarded. Applicants from academic institutions and small businesses (< 5 employees or < $1M annual revenue) are encouraged to apply. Awardees will be announced Friday, February 26, 2021 and invited to complete the grant process to receive the grant award. For more information or questions about the HumaScholar Grant, please email info@humabiologics.com.
Humabiologics, Inc. is announcing its first HumaScholar Grant. Each HumaScholar will receive a $3,000 research grant in the form of credit to utilize human-derived biomaterials from Humabiologics. All proposed work must be completed between March 8th and May 28, 2021. Humabiologics will not own any rights for intellectual property, publications, or any other rights generated from the use of the grant money. The application deadline is 11:59pm EST on Friday, February 19, 2021. A total of 20 grants will be awarded. Applicants from academic institutions and small businesses (< 5 employees or < $1M annual revenue) are encouraged to apply. Awardees will be announced Friday, February 26, 2021 and invited to complete the grant process to receive the grant award. For more information or questions about the HumaScholar Grant, please email info@humabiologics.com.
17 companies were chosen to participate in the program, including Humabiologics.
By Amanda Goodman, June 24th, 2020
Ask any college student or soon-to-be college student about internships and they’ll probably tell you something similar to what Dana Rasmussen had to say.
“I think internships are a unique way for students to gain real-world experience in a chosen field to grow their skills, make connections and really see if something is a good fit for their career goals.”
Rasmussen is a 20-year-old health entrepreneurship and innovation major in the Edson College of Nursing and Health Innovation at ASU. Like many of her undergraduate peers, she was planning on doing an internship this summer. But, as the coronavirus reached pandemic levels, it became clear many traditional internships were not going to be happening, leaving Rasmussen and a lot of her peers scrambling.
Recognizing the need for an alternative to the quickly vanishing in-person internships, Clinical Professor Rick Hall, director of the HEALab and senior director of health innovation programs at Edson College, had an idea.
“We have great relationships with health-related businesses locally and around the country, some of whom have come through the HEALab or other ASU entrepreneurship programs, so why not tap that network to connect students with businesses in need to work on meaningful projects that would benefit everyone,” said Hall.
And so, the HEALab developed and launched the Healthcare Innovation Virtual Internship in just a matter of weeks.
Hall said he knew there would be interest in the program but he wasn’t prepared for just how much interest: “Even though we knew there was a need, the demand was still surprising and the quality of applicants we got on both sides of this surpassed our expectations.”
In total they had 90 students apply from 14 states and three countries. This included high school students and undergraduates. Rasmussen was one of them.
“If this wasn't available, I would not have been able to participate in an internship this summer. I am so grateful that the HEALab team was able to put together such a well-planned virtual internship experience on such short notice,” Rasmussen said.
In all, 17 companies applied to participate, including Humabiologics.
Mohammad Albanna, the founder and CEO of Humabiologics, has a long-standing relationship with the university and says offering internships is one of the ways he can give back to the community, while also helping to develop local talent.
“When we provide internships to students in Arizona, not only do we empower and increase the pool of talent available for us as Arizona companies to leverage in the future, but also for other industries outside the state,” he explained.
During the program, Humabiologics hosted six students who worked in teams to conduct a thorough market analysis on products and explore opportunities of untapped markets.
Albanna described the experience of working with the students as fantastic and said they were happy with “the amount of time and dedication these students put into these projects and the outcomes we got, which will help in our future business decisions.”
This internship program was not for credit, serving strictly for experience, resume-building and networking. The HEALab team coordinated a two-week structured internship, pairing students with businesses who then had them work on specific projects. From there, it was up to the participants to determine what happened next.
Albanna says they hired an intern from the program due to “his impressive quality of work and ability and speed in learning new things.”
Rasmussen worked with Securisyn Medical, a medical technology company and past participant in the Mayo Clinic and ASU MedTech Accelerator, for her internship. The project she was part of revolved around future product development research, an area that was new to her. Even so, she was able to pick it up quickly, impressing herself and the team at Securisyn who wanted to continue the relationship.
“It is because of this opportunity that I have been able to intern directly with Securisyn for the whole summer, growing my skills and network,” she said.
While the Healthcare Innovation Virtual Internship started out as an alternative option, Hall confirms that their early success has them considering doing this again.
“We know that we can do this now and do it well," he said. "So if we can fulfill a need by creating new and interesting opportunities for students around the globe to gain real-world experience with health care businesses in a virtual environment, I think that’s worth seriously looking into.”
About the HEALab
In partnership with ASU’s E+I programs, the development of Edson College of Nursing and Health Innovation's Health Entrepreneurship Accelerator Lab is the first-ever accelerator for students, faculty and the community at ASU to launch initiatives that focus entirely on health and health care solutions. Through outreach, programming, networking, strategic partnerships and mentorship, the lab supports startup activities by connecting students to its own resources, the knowledge base of the expert faculty and the resources of the university and community.
A $1 million seed funding is taking Humabiologics, Inc. closer to the market with its unique biomedical product. The Phoenix company, among the 2019 finalists in the BIO International Startup Stadium, is a regenerative medicine company founded by scientists and tissue industry experts.
Last year, one of those finalists was Humabiologics, a company that extracts collagen, one of the building blocks of human organs, from donated tissue and sells it to researchers. This can be used by scientists to recreate miniaturized organs or skin in the lab.
PHOENIX, Ariz.– Humabiologics Inc., a regenerative medicine company founded by scientists and tissue industry experts, announced today it has successfully raised $1 million in seed funding.
Six bioscience companies creating innovative solutions to improve regenerative medicine, spinal surgery, sleep health, medical payments, the food supply, and even ear cleaning have been selected for the 2020 Flinn Foundation Bioscience Entrepreneurship Program.
Humabiologics provides a stable supply of high–quality, human-derived biomaterials for tissue engineering, research, and regenerative medicine. The company, dedicated to bridging the gap between researchers and the gift of donated human tissues, partners with academic and industry institutions to develop biomaterials to address debilitating diseases and improve the quality of life for patients.
Eight Arizona biotech and tech startups landed funding on Feb. 20 from a Valley pitch contest and an entrepreneurship program.
Humabiologics, a Phoenix-based startup that extends the gift of donation to provide human-derived biomaterials and stem cells to empower tomorrow’s innovations.
Copyright © 2018 Humabiologics, Inc - All Rights Reserved.
Human Tissue ECM Hydrogels Bioinks and Bioprinting Human Gelatin Human Collagen
This website uses cookies. By continuing to use this site, you accept our use of cookies.